These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

756 related articles for article (PubMed ID: 33122346)

  • 21. Neoantigen Cancer Vaccines: Real Opportunity or Another Illusion?
    Manoutcharian K; Guzman Valle J; Gevorkian G
    Arch Immunol Ther Exp (Warsz); 2021 Apr; 69(1):12. PubMed ID: 33909124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination.
    Roy DG; Geoffroy K; Marguerie M; Khan ST; Martin NT; Kmiecik J; Bobbala D; Aitken AS; de Souza CT; Stephenson KB; Lichty BD; Auer RC; Stojdl DF; Bell JC; Bourgeois-Daigneault MC
    Nat Commun; 2021 May; 12(1):2626. PubMed ID: 33976179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Personalized cancer vaccination in head and neck cancer.
    Shibata H; Zhou L; Xu N; Egloff AM; Uppaluri R
    Cancer Sci; 2021 Mar; 112(3):978-988. PubMed ID: 33368875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved.
    Fritsch EF; Burkhardt UE; Hacohen N; Wu CJ
    Cancer Immunol Res; 2020 Dec; 8(12):1465-1469. PubMed ID: 33262163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines.
    Ott PA; Dotti G; Yee C; Goff SL
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e70-e78. PubMed ID: 31099621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sulfonium-Stapled Peptides-Based Neoantigen Delivery System for Personalized Tumor Immunotherapy and Prevention.
    Zhang Y; Jiang L; Huang S; Lian C; Liang H; Xing Y; Liu J; Tian X; Liu Z; Wang R; An Y; Lu F; Pan Y; Han W; Li Z; Yin F
    Adv Sci (Weinh); 2024 Jun; 11(24):e2307754. PubMed ID: 38605600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Personalized cancer vaccines: adjuvants are important, too.
    Gouttefangeas C; Rammensee HG
    Cancer Immunol Immunother; 2018 Dec; 67(12):1911-1918. PubMed ID: 29644387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Getting personal with neoantigen-based therapeutic cancer vaccines.
    Hacohen N; Fritsch EF; Carter TA; Lander ES; Wu CJ
    Cancer Immunol Res; 2013 Jul; 1(1):11-5. PubMed ID: 24777245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Personalized cancer neoantigen vaccines come of age.
    Chu Y; Liu Q; Wei J; Liu B
    Theranostics; 2018; 8(15):4238-4246. PubMed ID: 30128050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
    Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.
    Chen X; Yang J; Wang L; Liu B
    Theranostics; 2020; 10(13):6011-6023. PubMed ID: 32483434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Personalized Dendritic-cell-based Vaccines Targeting Cancer Neoantigens.
    Kamigaki T; Takimoto R; Okada S; Ibe H; Oguma E; Goto S
    Anticancer Res; 2024 Sep; 44(9):3713-3724. PubMed ID: 39197920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium.
    Guo Y; Chen Y; Liu X; Min JJ; Tan W; Zheng JH
    Cancer Lett; 2020 Jan; 469():102-110. PubMed ID: 31666180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.
    Mørk SK; Skadborg SK; Albieri B; Draghi A; Bol K; Kadivar M; Westergaard MCW; Stoltenborg Granhøj J; Borch A; Petersen NV; Thuesen N; Rasmussen IS; Andreasen LV; Dohn RB; Yde CW; Noergaard N; Lorentzen T; Soerensen AB; Kleine-Kohlbrecher D; Jespersen A; Christensen D; Kringelum J; Donia M; Hadrup SR; Marie Svane I
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38782542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery.
    de Sousa E; Lérias JR; Beltran A; Paraschoudi G; Condeço C; Kamiki J; António PA; Figueiredo N; Carvalho C; Castillo-Martin M; Wang Z; Ligeiro D; Rao M; Maeurer M
    Front Immunol; 2021; 12():592031. PubMed ID: 34335558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice.
    Barajas A; Amengual-Rigo P; Pons-Grífols A; Ortiz R; Gracia Carmona O; Urrea V; de la Iglesia N; Blanco-Heredia J; Anjos-Souza C; Varela I; Trinité B; Tarrés-Freixas F; Rovirosa C; Lepore R; Vázquez M; de Mattos-Arruda L; Valencia A; Clotet B; Aguilar-Gurrieri C; Guallar V; Carrillo J; Blanco J
    J Transl Med; 2024 Jan; 22(1):14. PubMed ID: 38172991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.
    Pan RY; Chung WH; Chu MT; Chen SJ; Chen HC; Zheng L; Hung SI
    J Immunol Res; 2018; 2018():4325874. PubMed ID: 30662919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines.
    Roesler AS; Anderson KS
    Methods Mol Biol; 2022; 2410():649-670. PubMed ID: 34914074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.